An Open-Label Single Dose Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Seltorexant (Primary)
- Indications Insomnia; Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 09 Aug 2017 Planned End Date changed from 1 May 2017 to 20 Oct 2017.
- 09 Aug 2017 Planned primary completion date changed from 1 May 2017 to 20 Oct 2017.
- 09 Aug 2017 Status changed from completed to recruiting.